-
市场
-
产品
-
资讯
-
Moo社区
-
课堂
-
查看更多
-
功能介绍
-
费用费用透明,无最低余额限制
投资选择、功能介绍、费用相关信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 浅色
Iovance Biotherapeutics (NASDAQ:IOVA) Stock Price Up 5.1%
Iovance Biotherapeutics (NASDAQ:IOVA) Stock Price Up 5.1%
Iovance Biotherapeutics, Inc. (NASDAQ:IOVA – Get Rating)'s share price shot up 5.1% during trading on Thursday . The company traded as high as $11.63 and last traded at $11.63. 59,817 shares changed hands during trading, a decline of 97% from the average session volume of 2,000,791 shares. The stock had previously closed at $11.07.
Wall Street Analyst Weigh In
A number of analysts recently weighed in on the stock. Truist Financial cut their target price on shares of Iovance Biotherapeutics to $18.00 in a research note on Tuesday, August 23rd. The Goldman Sachs Group lowered their target price on shares of Iovance Biotherapeutics from $64.00 to $18.00 and set a "buy" rating for the company in a research note on Friday, July 1st. Chardan Capital lowered their price objective on Iovance Biotherapeutics from $31.00 to $30.00 in a research report on Friday, August 5th. Piper Sandler cut their target price on Iovance Biotherapeutics from $20.00 to $13.00 and set a "neutral" rating on the stock in a research report on Friday, May 27th. Finally, Robert W. Baird lowered their price target on Iovance Biotherapeutics from $34.00 to $25.00 and set an "outperform" rating for the company in a report on Friday, August 5th. One analyst has rated the stock with a sell rating, two have issued a hold rating and eight have assigned a buy rating to the stock. According to MarketBeat.com, the company has an average rating of "Moderate Buy" and an average target price of $23.80.
Get Iovance Biotherapeutics alerts:Iovance Biotherapeutics Stock Up 6.3 %
The business's fifty day moving average price is $11.83 and its 200 day moving average price is $12.90.
Iovance Biotherapeutics (NASDAQ:IOVA – Get Rating) last posted its quarterly earnings data on Thursday, August 4th. The biotechnology company reported ($0.63) earnings per share for the quarter, missing analysts' consensus estimates of ($0.60) by ($0.03). During the same period in the prior year, the business earned ($0.53) earnings per share. As a group, sell-side analysts anticipate that Iovance Biotherapeutics, Inc. will post -2.53 EPS for the current fiscal year.Institutional Trading of Iovance Biotherapeutics
Several hedge funds have recently made changes to their positions in IOVA. Herold Advisors Inc. acquired a new stake in Iovance Biotherapeutics in the first quarter valued at about $33,000. Spire Wealth Management purchased a new stake in shares of Iovance Biotherapeutics in the first quarter valued at approximately $47,000. Lazard Asset Management LLC grew its holdings in Iovance Biotherapeutics by 38.5% during the first quarter. Lazard Asset Management LLC now owns 3,357 shares of the biotechnology company's stock worth $55,000 after acquiring an additional 934 shares during the period. Retirement Group LLC raised its position in Iovance Biotherapeutics by 85.1% in the first quarter. Retirement Group LLC now owns 4,350 shares of the biotechnology company's stock worth $72,000 after acquiring an additional 2,000 shares in the last quarter. Finally, MetLife Investment Management LLC acquired a new stake in Iovance Biotherapeutics in the first quarter valued at $83,000.
About Iovance Biotherapeutics
(Get Rating)
Iovance Biotherapeutics, Inc, a clinical-stage biotechnology company, focuses on developing and commercializing cancer immunotherapy products to harness the power of a patient's immune system to eradicate cancer cells. It has six ongoing phase 2 clinical studies, including C-144-01, of its lead product candidate, lifileucel, for the treatment of metastatic melanoma; C-145-04, of its product candidate lifileucel for recurrent, metastatic, or persistent cervical cancer; and C-145-03, of its product candidate LN-145, for recurrent and/or metastatic head and neck squamous cell carcinoma.
Read More
- Get a free copy of the StockNews.com research report on Iovance Biotherapeutics (IOVA)
- Why Medical Products Maker Repligen May Be A Potential Buy
- At 10%, Is Arbor Realty Trust Dividend Worth It?
- Investors Should Tune Into RF Industries
- 2 Reasons Netflix Might Have Just Bottomed Out
- Murphy USA Outperforming Other Mid-caps, But Is It A Buy Now?
Receive News & Ratings for Iovance Biotherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Iovance Biotherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
Iovance Biotherapeutics, Inc. (NASDAQ:IOVA – Get Rating)'s share price shot up 5.1% during trading on Thursday . The company traded as high as $11.63 and last traded at $11.63. 59,817 shares changed hands during trading, a decline of 97% from the average session volume of 2,000,791 shares. The stock had previously closed at $11.07.
在周四的交易中,IOVANCE BioTreateutics,Inc.(纳斯达克代码:IOVA-GET Rating)的股价飙升了5.1%。该公司股价一度涨至11.63美元,最新报11.63美元。59,817股股票在交易中易手,较2,000,791股的平均交易量下跌了97%。该股此前收盘报11.07美元。
Wall Street Analyst Weigh In
华尔街分析师也加入进来
A number of analysts recently weighed in on the stock. Truist Financial cut their target price on shares of Iovance Biotherapeutics to $18.00 in a research note on Tuesday, August 23rd. The Goldman Sachs Group lowered their target price on shares of Iovance Biotherapeutics from $64.00 to $18.00 and set a "buy" rating for the company in a research note on Friday, July 1st. Chardan Capital lowered their price objective on Iovance Biotherapeutics from $31.00 to $30.00 in a research report on Friday, August 5th. Piper Sandler cut their target price on Iovance Biotherapeutics from $20.00 to $13.00 and set a "neutral" rating on the stock in a research report on Friday, May 27th. Finally, Robert W. Baird lowered their price target on Iovance Biotherapeutics from $34.00 to $25.00 and set an "outperform" rating for the company in a report on Friday, August 5th. One analyst has rated the stock with a sell rating, two have issued a hold rating and eight have assigned a buy rating to the stock. According to MarketBeat.com, the company has an average rating of "Moderate Buy" and an average target price of $23.80.
一些分析师最近加入了对该股的看法。Truist Financial在8月23日(星期二)的一份研究报告中将Iovance BioTreateutics的目标价下调至18.00美元。7月1日,高盛夫妇在一份研究报告中将Iovance BioTreateutics的目标价从64.00美元下调至18.00美元,并为该公司设定了买入评级。在8月5日星期五的一份研究报告中,Chardan Capital将Iovance BioTreateutics的目标价从31.00美元下调至30.00美元。派珀·桑德勒在5月27日周五的一份研究报告中将其对Iovance BioTreateutics的目标价从20.00美元下调至13.00美元,并将该股的评级定为“中性”。最后,罗伯特·W·贝尔德在8月5日星期五的一份报告中将Iovance BioTreateutics的目标价从34.00美元下调至25.00美元,并为该公司设定了“跑赢大盘”的评级。一名分析师对该股的评级为卖出,两名分析师发布了持有评级,八名分析师对该股给予了买入评级。根据MarketBeat.com的数据,该公司的平均评级为“中等买入”,平均目标价为23.80美元.
Iovance Biotherapeutics Stock Up 6.3 %
Iovance BioTreatetics股价上涨6.3%
The business's fifty day moving average price is $11.83 and its 200 day moving average price is $12.90.
该业务的50日移动均线价格为11.83美元,200日移动均线价格为12.90美元。
Institutional Trading of Iovance Biotherapeutics
Iovance生物疗法的制度性交易
Several hedge funds have recently made changes to their positions in IOVA. Herold Advisors Inc. acquired a new stake in Iovance Biotherapeutics in the first quarter valued at about $33,000. Spire Wealth Management purchased a new stake in shares of Iovance Biotherapeutics in the first quarter valued at approximately $47,000. Lazard Asset Management LLC grew its holdings in Iovance Biotherapeutics by 38.5% during the first quarter. Lazard Asset Management LLC now owns 3,357 shares of the biotechnology company's stock worth $55,000 after acquiring an additional 934 shares during the period. Retirement Group LLC raised its position in Iovance Biotherapeutics by 85.1% in the first quarter. Retirement Group LLC now owns 4,350 shares of the biotechnology company's stock worth $72,000 after acquiring an additional 2,000 shares in the last quarter. Finally, MetLife Investment Management LLC acquired a new stake in Iovance Biotherapeutics in the first quarter valued at $83,000.
几家对冲基金最近改变了他们在Iova的头寸。Herold Advisors Inc.在第一季度收购了Iovance BioTreateutics的新股份,价值约3.3万美元。Spire Wealth Management在第一季度购买了Iovance BioTreateutics的新股份,价值约47,000美元。Lazard Asset Management LLC在第一季度增持了Iovance BioTreateutics 38.5%的股份。Lazard Asset Management LLC在此期间额外收购了934股,现在拥有3357股这家生物技术公司的股票,价值5.5万美元。退休集团LLC在第一季度将其在Iovance BioTreateutics的头寸提高了85.1%。在上个季度增持了2,000股后,退休集团现在持有这家生物技术公司4,350股股票,价值72,000美元。最后,大都会人寿投资管理有限责任公司在第一季度收购了Iovance BioTreateutics的新股份,价值8.3万美元。
About Iovance Biotherapeutics
关于爱万斯生物治疗学
(Get Rating)
(获取评级)
Iovance Biotherapeutics, Inc, a clinical-stage biotechnology company, focuses on developing and commercializing cancer immunotherapy products to harness the power of a patient's immune system to eradicate cancer cells. It has six ongoing phase 2 clinical studies, including C-144-01, of its lead product candidate, lifileucel, for the treatment of metastatic melanoma; C-145-04, of its product candidate lifileucel for recurrent, metastatic, or persistent cervical cancer; and C-145-03, of its product candidate LN-145, for recurrent and/or metastatic head and neck squamous cell carcinoma.
Iovance BioTreateutics,Inc.是一家临床阶段的生物技术公司,专注于开发癌症免疫治疗产品并将其商业化,以利用患者免疫系统的力量根除癌细胞。该公司正在进行6项第二阶段临床研究,包括其主要候选产品lifileucel的C-144-01,用于治疗转移性黑色素瘤;C-145-04,其候选产品lifileucel,用于复发、转移或持续性宫颈癌;以及C-145-03,其候选产品LN-145,用于治疗复发和/或转移性头颈部鳞状细胞癌。
Read More
阅读更多内容
- Get a free copy of the StockNews.com research report on Iovance Biotherapeutics (IOVA)
- Why Medical Products Maker Repligen May Be A Potential Buy
- At 10%, Is Arbor Realty Trust Dividend Worth It?
- Investors Should Tune Into RF Industries
- 2 Reasons Netflix Might Have Just Bottomed Out
- Murphy USA Outperforming Other Mid-caps, But Is It A Buy Now?
- 免费获取StockNews.com关于Iovance生物疗法(IOVA)的研究报告
- 为什么医疗产品制造商Repligen可能成为潜在收购对象
- 在10%的水平上,Arbor Realty Trust的股息值得吗?
- 投资者应关注RF Industries
- Netflix可能刚刚触底的两个原因
- 墨菲美国的表现好于其他中型股,但它现在值得吗?
Receive News & Ratings for Iovance Biotherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Iovance Biotherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
获得《爱的生物疗法日报》的新闻和评级-在下面输入您的电子邮件地址,通过MarketBeat.com的免费每日电子邮件时事通讯接收对Iovance BioTreateutics和相关公司的最新新闻和分析师评级的每日简要摘要。
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国,moomoo上的投资产品和服务由Moomoo Financial Inc.提供,一家受美国证券交易委员会(SEC)监管的持牌主体。 Moomoo Financial Inc.是金融业监管局(FINRA)和证券投资者保护公司(SIPC)的成员。
在新加坡,moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供,该公司受新加坡金融管理局(MAS)监管(牌照号码︰CMS101000) ,持有资本市场服务牌照 (CMS) ,持有财务顾问豁免(Exempt Financial Adviser)资质。本内容未经新加坡金融管理局的审查。
在澳大利亚,moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供,该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构(AFSL No. 224663)。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件,这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大,通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供,并受加拿大投资监管机构(CIRO)监管。
在马来西亚,moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供,该公司受马来西亚证券监督委员会(SC)监管(牌照号码︰eCMSL/A0397/2024) ,持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
风险及免责提示
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国,moomoo上的投资产品和服务由Moomoo Financial Inc.提供,一家受美国证券交易委员会(SEC)监管的持牌主体。 Moomoo Financial Inc.是金融业监管局(FINRA)和证券投资者保护公司(SIPC)的成员。
在新加坡,moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供,该公司受新加坡金融管理局(MAS)监管(牌照号码︰CMS101000) ,持有资本市场服务牌照 (CMS) ,持有财务顾问豁免(Exempt Financial Adviser)资质。本内容未经新加坡金融管理局的审查。
在澳大利亚,moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供,该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构(AFSL No. 224663)。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件,这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大,通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供,并受加拿大投资监管机构(CIRO)监管。
在马来西亚,moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供,该公司受马来西亚证券监督委员会(SC)监管(牌照号码︰eCMSL/A0397/2024) ,持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用浏览器的分享功能,分享给你的好友吧